75 related articles for article (PubMed ID: 17534400)
1. Anti-CD3 scFv-B7.1 fusion protein expressed on the surface of HeLa cells provokes potent T-lymphocyte activation and cytotoxicity.
Yang ZM; Li EM; Lai BC; Wang YL; Si LS
Biochem Cell Biol; 2007 Apr; 85(2):196-202. PubMed ID: 17534400
[TBL] [Abstract][Full Text] [Related]
2. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins.
Holliger P; Manzke O; Span M; Hawkins R; Fleischmann B; Qinghua L; Wolf J; Diehl V; Cochet O; Winter G; Bohlen H
Cancer Res; 1999 Jun; 59(12):2909-16. PubMed ID: 10383154
[TBL] [Abstract][Full Text] [Related]
3. Autocrine costimulation: tumor-specific CD28-mediated costimulation of T cells by in situ production of a bifunctional B7-anti-CEA diabody fusion protein.
Blanco B; Holliger P; Alvarez-Vallina L
Cancer Gene Ther; 2002 Mar; 9(3):275-81. PubMed ID: 11896444
[TBL] [Abstract][Full Text] [Related]
4. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
Biburger M; Weth R; Wels WS
J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
[TBL] [Abstract][Full Text] [Related]
5. A mutant B7-1/Ig fusion protein that selectively binds to CTLA-4 ameliorates anti-tumor DNA vaccination and counters regulatory T cell activity.
Chakrabarti R; Zhou ZF; Chang Y; Prud'homme GJ
Vaccine; 2005 Aug; 23(37):4553-64. PubMed ID: 15919138
[TBL] [Abstract][Full Text] [Related]
6. Helper effector function of human T cells stimulated by anti-CD3 mAb can be enhanced by co-stimulatory signals and is partially dependent on CD40-CD40 ligand interaction.
Kwekkeboom J; de Rijk D; Kasran A; Barcy S; de Groot C; de Boer M
Eur J Immunol; 1994 Mar; 24(3):508-17. PubMed ID: 7510232
[TBL] [Abstract][Full Text] [Related]
7. Suppression of human T-cell responses to beta-cells by activation of B7-H4 pathway.
Ou D; Wang X; Metzger DL; Ao Z; Pozzilli P; James RF; Chen L; Warnock GL
Cell Transplant; 2006; 15(5):399-410. PubMed ID: 16970282
[TBL] [Abstract][Full Text] [Related]
8. A new model of trispecific antibody resulting the cytotoxicity directed against tumor cells.
Song LP; Cheng JL; Wang XB; Zhang Z; Fang M; Zhou ZY; Huang HL
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Jun; 35(6):503-10. PubMed ID: 12796809
[TBL] [Abstract][Full Text] [Related]
9. Construction and molecular characterization of human chimeric T-cell antigen receptors specific for carcinoembryonic antigen.
Shirasu N; Shibaguci H; Kuroki M; Yamada H; Kuroki M
Anticancer Res; 2010 Jul; 30(7):2731-8. PubMed ID: 20683006
[TBL] [Abstract][Full Text] [Related]
10. [Eukaryotic expression of anti-CD3 single chain Fv antibody gene and the characterization of its bioactivities].
Yang ZM; Hu JS; Lai BC; Wang YL; Si LS
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 Sep; 20(5):552-5. PubMed ID: 15367345
[TBL] [Abstract][Full Text] [Related]
11. Stable expression of chimeric anti-CD3 receptors on mammalian cells for stimulation of antitumor immunity.
Liao KW; Chen BM; Liu TB; Tzou SC; Lin YM; Lin KF; Su CI; Roffler SR
Cancer Gene Ther; 2003 Oct; 10(10):779-90. PubMed ID: 14502231
[TBL] [Abstract][Full Text] [Related]
12. T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis.
Hombach A; Sent D; Schneider C; Heuser C; Koch D; Pohl C; Seliger B; Abken H
Cancer Res; 2001 Mar; 61(5):1976-82. PubMed ID: 11280755
[TBL] [Abstract][Full Text] [Related]
13. B7.1 is a quantitatively stronger costimulus than B7.2 in the activation of naive CD8+ TCR-transgenic T cells.
Fields PE; Finch RJ; Gray GS; Zollner R; Thomas JL; Sturmhoefel K; Lee K; Wolf S; Gajewski TF; Fitch FW
J Immunol; 1998 Nov; 161(10):5268-75. PubMed ID: 9820499
[TBL] [Abstract][Full Text] [Related]
14. B7/CD28 but not LFA-3/CD2 interactions can provide 'third-party' co-stimulation for human T-cell activation.
Sansom DM; Wilson A; Boshell M; Lewis J; Hall ND
Immunology; 1993 Oct; 80(2):242-7. PubMed ID: 7505258
[TBL] [Abstract][Full Text] [Related]
15. Induction of hyporesponsiveness in human lymphocytes-T despite their expression of both the co-receptor CD28 and its ligand B7.
Friccius H; Siegels-Hübenthal P; Rehbein A; Schlotz E; Pawelec G
Cell Immunol; 1993 Oct; 151(2):283-90. PubMed ID: 7691420
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous ligation of CD5 and CD28 on resting T lymphocytes induces T cell activation in the absence of T cell receptor/CD3 occupancy.
Verwilghen J; Vandenberghe P; Wallays G; de Boer M; Anthony N; Panayi GS; Ceuppens JL
J Immunol; 1993 Feb; 150(3):835-46. PubMed ID: 7678624
[TBL] [Abstract][Full Text] [Related]
17. CD 80(B7-1) expression on human tumor cell lines and its costimulatory signals for T cell proliferation and cytokine production.
Yan J; Ma B; Guo X; Sun Y; Zhang J; Zhang H
Chin Med J (Engl); 1998 Mar; 111(3):269-71. PubMed ID: 10374432
[TBL] [Abstract][Full Text] [Related]
18. Targeting of T cells to CEA-expressing tumor cells by chimeric immune receptors with a highly specific single-chain anti-CEA activity.
Arakawa F; Shibaguchi H; Xu Z; Kuroki M
Anticancer Res; 2002; 22(6C):4285-9. PubMed ID: 12553071
[TBL] [Abstract][Full Text] [Related]
19. CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL.
Lanier LL; O'Fallon S; Somoza C; Phillips JH; Linsley PS; Okumura K; Ito D; Azuma M
J Immunol; 1995 Jan; 154(1):97-105. PubMed ID: 7527824
[TBL] [Abstract][Full Text] [Related]
20. Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors.
Alvarez-Vallina L; Hawkins RE
Eur J Immunol; 1996 Oct; 26(10):2304-9. PubMed ID: 8898938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
